Indeed, a recently characterised enzymatically stable and long-acting AVP analogue, namely Ac3IV, that acts exclusively at V1a and V1b receptors, possesses notable exciting therapeutic potential for diabetes [5]. The gene discussed is AVPR1B; the disease is diabetes mellitus.